Varicella-Zoster Virus–Specific Immune Responses in Elderly Recipients of a Herpes Zoster Vaccine
BackgroundA double-blind, placebo-controlled trial that involved 38,546 subjects ⩾60 years old demonstrated efficacy of a high-potency live-attenuated Oka/Merck varicella-zoster virus (VZV) vaccine. The trial included an immunology substudy to determine the relationship of VZV-specific immune respon...
Saved in:
| Published in | The Journal of infectious diseases Vol. 197; no. 6; pp. 825 - 835 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Chicago, IL
The University of Chicago Press
15.03.2008
University of Chicago Press |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | BackgroundA double-blind, placebo-controlled trial that involved 38,546 subjects ⩾60 years old demonstrated efficacy of a high-potency live-attenuated Oka/Merck varicella-zoster virus (VZV) vaccine. The trial included an immunology substudy to determine the relationship of VZV-specific immune responses to vaccination and clinical outcome MethodsThe immunology substudy enrolled 1395 subjects at 2 sites where blood samples obtained prior to vaccination, at 6 weeks after vaccination, and at 1, 2, and 3 years thereafter were tested for VZV-specific cell-mediated immunity (VZV-CMI) by γ-interferon ELISPOT and responder cell frequency assays and for VZV antibody by glycoprotein ELISA ResultsVZV-CMI and VZV antibodies were significantly increased in vaccine recipients at 6 weeks after vaccination. The vaccine-induced increases in VZV-CMI persisted during the 3 years of follow-up, although their magnitude decreased over time. The magnitude of these VZV-specific immune responses was greater in subjects 60–69 years old than in subjects ⩾70 years old ConclusionsThe zoster vaccine induced a significant increase in VZV-CMI and VZV antibody. The magnitude and duration of the boost in VZV-CMI in vaccine recipients and the relationship of this boost to age paralleled the clinical effects of the vaccine observed during the efficacy trial. These findings support the hypothesis that boosting VZV-CMI protects older adults against herpes zoster and postherpetic neuralgia |
|---|---|
| AbstractList | A double-blind, placebo-controlled trial that involved 38,546 subjects > or =60 years old demonstrated efficacy of a high-potency live-attenuated Oka/Merck varicella-zoster virus (VZV) vaccine. The trial included an immunology substudy to determine the relationship of VZV-specific immune responses to vaccination and clinical outcome.BACKGROUNDA double-blind, placebo-controlled trial that involved 38,546 subjects > or =60 years old demonstrated efficacy of a high-potency live-attenuated Oka/Merck varicella-zoster virus (VZV) vaccine. The trial included an immunology substudy to determine the relationship of VZV-specific immune responses to vaccination and clinical outcome.The immunology substudy enrolled 1395 subjects at 2 sites where blood samples obtained prior to vaccination, at 6 weeks after vaccination, and at 1, 2, and 3 years thereafter were tested for VZV-specific cell-mediated immunity (VZV-CMI) by gamma-interferon ELISPOT and responder cell frequency assays and for VZV antibody by glycoprotein ELISA.METHODSThe immunology substudy enrolled 1395 subjects at 2 sites where blood samples obtained prior to vaccination, at 6 weeks after vaccination, and at 1, 2, and 3 years thereafter were tested for VZV-specific cell-mediated immunity (VZV-CMI) by gamma-interferon ELISPOT and responder cell frequency assays and for VZV antibody by glycoprotein ELISA.VZV-CMI and VZV antibodies were significantly increased in vaccine recipients at 6 weeks after vaccination. The vaccine-induced increases in VZV-CMI persisted during the 3 years of follow-up, although their magnitude decreased over time. The magnitude of these VZV-specific immune responses was greater in subjects 60-69 years old than in subjects > or =70 years old.RESULTSVZV-CMI and VZV antibodies were significantly increased in vaccine recipients at 6 weeks after vaccination. The vaccine-induced increases in VZV-CMI persisted during the 3 years of follow-up, although their magnitude decreased over time. The magnitude of these VZV-specific immune responses was greater in subjects 60-69 years old than in subjects > or =70 years old.The zoster vaccine induced a significant increase in VZV-CMI and VZV antibody. The magnitude and duration of the boost in VZV-CMI in vaccine recipients and the relationship of this boost to age paralleled the clinical effects of the vaccine observed during the efficacy trial. These findings support the hypothesis that boosting VZV-CMI protects older adults against herpes zoster and postherpetic neuralgia.CONCLUSIONSThe zoster vaccine induced a significant increase in VZV-CMI and VZV antibody. The magnitude and duration of the boost in VZV-CMI in vaccine recipients and the relationship of this boost to age paralleled the clinical effects of the vaccine observed during the efficacy trial. These findings support the hypothesis that boosting VZV-CMI protects older adults against herpes zoster and postherpetic neuralgia. A double-blind, placebo-controlled trial that involved 38,546 subjects > or =60 years old demonstrated efficacy of a high-potency live-attenuated Oka/Merck varicella-zoster virus (VZV) vaccine. The trial included an immunology substudy to determine the relationship of VZV-specific immune responses to vaccination and clinical outcome. The immunology substudy enrolled 1395 subjects at 2 sites where blood samples obtained prior to vaccination, at 6 weeks after vaccination, and at 1, 2, and 3 years thereafter were tested for VZV-specific cell-mediated immunity (VZV-CMI) by gamma-interferon ELISPOT and responder cell frequency assays and for VZV antibody by glycoprotein ELISA. VZV-CMI and VZV antibodies were significantly increased in vaccine recipients at 6 weeks after vaccination. The vaccine-induced increases in VZV-CMI persisted during the 3 years of follow-up, although their magnitude decreased over time. The magnitude of these VZV-specific immune responses was greater in subjects 60-69 years old than in subjects > or =70 years old. The zoster vaccine induced a significant increase in VZV-CMI and VZV antibody. The magnitude and duration of the boost in VZV-CMI in vaccine recipients and the relationship of this boost to age paralleled the clinical effects of the vaccine observed during the efficacy trial. These findings support the hypothesis that boosting VZV-CMI protects older adults against herpes zoster and postherpetic neuralgia. BackgroundA double-blind, placebo-controlled trial that involved 38,546 subjects ⩾60 years old demonstrated efficacy of a high-potency live-attenuated Oka/Merck varicella-zoster virus (VZV) vaccine. The trial included an immunology substudy to determine the relationship of VZV-specific immune responses to vaccination and clinical outcome MethodsThe immunology substudy enrolled 1395 subjects at 2 sites where blood samples obtained prior to vaccination, at 6 weeks after vaccination, and at 1, 2, and 3 years thereafter were tested for VZV-specific cell-mediated immunity (VZV-CMI) by γ-interferon ELISPOT and responder cell frequency assays and for VZV antibody by glycoprotein ELISA ResultsVZV-CMI and VZV antibodies were significantly increased in vaccine recipients at 6 weeks after vaccination. The vaccine-induced increases in VZV-CMI persisted during the 3 years of follow-up, although their magnitude decreased over time. The magnitude of these VZV-specific immune responses was greater in subjects 60–69 years old than in subjects ⩾70 years old ConclusionsThe zoster vaccine induced a significant increase in VZV-CMI and VZV antibody. The magnitude and duration of the boost in VZV-CMI in vaccine recipients and the relationship of this boost to age paralleled the clinical effects of the vaccine observed during the efficacy trial. These findings support the hypothesis that boosting VZV-CMI protects older adults against herpes zoster and postherpetic neuralgia Background. A double-blind, placebo-controlled trial that involved 38,546 subjects .60 years old demonstrated efficacy of a high-potency live-attenuated Oka/Merck varicella-zoster virus (VZV) vaccine. The trial included an immunology substudy to determine the relationship of VZV-specific immune responses to vaccination and clinical outcome. Methods. The Immunology substudy enrolled 1395 subjects at 2 sites where blood samples obtained prior to vaccination, at 6 weeks after vaccination, and at 1, 2, and 3 years thereafter were tested for VZV-specific cell-mediated immunity (VZV-CMI) by g-interferon ELISPOT and responder cell frequency assays and for VZV antibody by glycoprotein ELISA. Results. VZV-CMI and VZV antibodies were significantly increased in vaccine recipients at 6 weeks after vaccination. The vaccine-induced increases in VZV-CMI persisted during the 3 years of follow-up, although their magnitude decreased over time. The magnitude of these VZV-specific immune responses was greater in subjects 60-69 years old than in subjects .70 years old. Conclusions. The zoster vaccine induced a significant increase in VZV-CMI and VZV antibody. The magnitude and duration of the boost in VZV-CMI in vaccine recipients and the relationship of this boost to age paralleled the clinical effects of the vaccine observed during the efficacy trial. These findings support the hypothesis that boosting VZV-CMI protects older adults against herpes zoster and postherpetic neuralgia. BackgroundA double-blind, placebo-controlled trial that involved 38,546 subjects ⩾60 years old demonstrated efficacy of a high-potency live-attenuated Oka/Merck varicella-zoster virus (VZV) vaccine. The trial included an immunology substudy to determine the relationship of VZV-specific immune responses to vaccination and clinical outcome MethodsThe immunology substudy enrolled 1395 subjects at 2 sites where blood samples obtained prior to vaccination, at 6 weeks after vaccination, and at 1, 2, and 3 years thereafter were tested for VZV-specific cell-mediated immunity (VZV-CMI) by γ-interferon ELISPOT and responder cell frequency assays and for VZV antibody by glycoprotein ELISA ResultsVZV-CMI and VZV antibodies were significantly increased in vaccine recipients at 6 weeks after vaccination. The vaccine-induced increases in VZV-CMI persisted during the 3 years of follow-up, although their magnitude decreased over time. The magnitude of these VZV-specific immune responses was greater in subjects 60-69 years old than in subjects ⩾70 years old ConclusionsThe zoster vaccine induced a significant increase in VZV-CMI and VZV antibody. The magnitude and duration of the boost in VZV-CMI in vaccine recipients and the relationship of this boost to age paralleled the clinical effects of the vaccine observed during the efficacy trial. These findings support the hypothesis that boosting VZV-CMI protects older adults against herpes zoster and postherpetic neuralgia Background. A double-blind, placebo-controlled trial that involved 38,546 subjects ≥60 years old demonstrated efficacy of a high-potency live-attenuated Oka/Merck varicella-zoster virus (VZV) vaccine. The trial included an immunology substudy to determine the relationship of VZV-specific immune responses to vaccination and clinical outcome. Methods. The immunology substudy enrolled 1395 subjects at 2 sites where blood samples obtained prior to vaccination, at 6 weeks after vaccination, and at 1, 2, and 3 years thereafter were tested for VZV-specific cell-mediated immunity (VZV-CMI) by γ-interferon ELISPOT and responder cell frequency assays and for VZV antibody by glycoprotein ELISA. Results. VZV-CMI and VZV antibodies were significantly increased in vaccine recipients at 6 weeks after vaccination. The vaccine-induced increases in VZV-CMI persisted during the 3 years of follow-up, although their magnitude decreased over time. The magnitude of these VZV-specific immune responses was greater in subjects 60-69 years old than in subjects ≥70 years old. Conclusions. The zoster vaccine induced a significant increase in VZV-CMI and VZV antibody. The magnitude and duration of the boost in VZV-CMI in vaccine recipients and the relationship of this boost to age paralleled the clinical effects of the vaccine observed during the efficacy trial. These findings support the hypothesis that boosting VZV-CMI protects older adults against herpes zoster and postherpetic neuralgia. Background A double-blind, placebo-controlled trial that involved 38,546 subjects ⩾60 years old demonstrated efficacy of a high-potency live-attenuated Oka/Merck varicella-zoster virus (VZV) vaccine. The trial included an immunology substudy to determine the relationship of VZV-specific immune responses to vaccination and clinical outcome Methods The immunology substudy enrolled 1395 subjects at 2 sites where blood samples obtained prior to vaccination, at 6 weeks after vaccination, and at 1, 2, and 3 years thereafter were tested for VZV-specific cell-mediated immunity (VZV-CMI) by γ-interferon ELISPOT and responder cell frequency assays and for VZV antibody by glycoprotein ELISA Results VZV-CMI and VZV antibodies were significantly increased in vaccine recipients at 6 weeks after vaccination. The vaccine-induced increases in VZV-CMI persisted during the 3 years of follow-up, although their magnitude decreased over time. The magnitude of these VZV-specific immune responses was greater in subjects 60–69 years old than in subjects ⩾70 years old Conclusions The zoster vaccine induced a significant increase in VZV-CMI and VZV antibody. The magnitude and duration of the boost in VZV-CMI in vaccine recipients and the relationship of this boost to age paralleled the clinical effects of the vaccine observed during the efficacy trial. These findings support the hypothesis that boosting VZV-CMI protects older adults against herpes zoster and postherpetic neuralgia |
| Author | Oxman, M. N. J. H. Zhang Irwin, M. R. Williams, H. Smith, J. G. Chan, I. S. F. Johnson, G. R. Levin, M. J. Straus, S. E. Harbecke, R. Clair, J. Gershon, A. Marchese, R. Stanley, H. Hayward, A. R. Caulfield, M. J. Weinberg, A. |
| Author_xml | – sequence: 1 givenname: M. J. surname: Levin fullname: Levin, M. J. – sequence: 2 givenname: M. N. surname: Oxman fullname: Oxman, M. N. – sequence: 3 fullname: J. H. Zhang – sequence: 4 givenname: G. R. surname: Johnson fullname: Johnson, G. R. – sequence: 5 givenname: H. surname: Stanley fullname: Stanley, H. – sequence: 6 givenname: A. R. surname: Hayward fullname: Hayward, A. R. – sequence: 7 givenname: M. J. surname: Caulfield fullname: Caulfield, M. J. – sequence: 8 givenname: M. R. surname: Irwin fullname: Irwin, M. R. – sequence: 9 givenname: J. G. surname: Smith fullname: Smith, J. G. – sequence: 10 givenname: J. surname: Clair fullname: Clair, J. – sequence: 11 givenname: I. S. F. surname: Chan fullname: Chan, I. S. F. – sequence: 12 givenname: H. surname: Williams fullname: Williams, H. – sequence: 13 givenname: R. surname: Harbecke fullname: Harbecke, R. – sequence: 14 givenname: R. surname: Marchese fullname: Marchese, R. – sequence: 15 givenname: S. E. surname: Straus fullname: Straus, S. E. – sequence: 16 givenname: A. surname: Gershon fullname: Gershon, A. – sequence: 17 givenname: A. surname: Weinberg fullname: Weinberg, A. |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20189905$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/18419349$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkstu1DAUQC3Uik4L_AEoLGBFwI7t2NkgoaF0KhWQCoxQN5bjuQGXxA52guiOf-AP-yV4yHTKQ4jVlXyPju9rH-047wChOwQ_JliWT3ghy6q8gWaEU5GXJaE7aIZxUeREVtUe2o_xHGPMaCluoj0iGakoq2bILHWwBtpW52c-DhCypQ1jvPz2_U0PxjbWZMddNzrITiH23kWImXXZYbuC0F6kR2N7C26ImW8ynS0g9Im4UmljrINbaLfRbYTbm3iA3r04fDtf5Cevj47nz05ywwkZcg2iZrLA5UoLnYJmhDNcS0ahKmrNNcWU1o3AKyaKhjC5Mho45TWAxGA4PUBPJ28_1h2sTCor6Fb1wXY6XCivrfo94-xH9cF_UQwnGxdJ8HAjCP7zCHFQnY0_h-PAj1GVFSGcS_xfsMAVY4lM4L1fS9rWcrWABDzYADoa3TZBO2Pjlivwen2YX_9ogo8xQHOtwmp9AWq6gAQ--gM0dtCD9euWbfs3fn_C_dj_W3l3Ys7j4MOWohhLWfD1NPIpb9PWv27zOnxSpaCCq8X7M3X68lW1nIvn6oj-AM7K1TQ |
| CODEN | JIDIAQ |
| CitedBy_id | crossref_primary_10_1093_gerona_gly287 crossref_primary_10_1186_s12879_021_05806_4 crossref_primary_10_3390_vaccines9040325 crossref_primary_10_5937_arhfarm1906469B crossref_primary_10_1016_j_it_2009_03_011 crossref_primary_10_1080_21645515_2019_1622974 crossref_primary_10_1016_j_vaccine_2014_12_024 crossref_primary_10_1016_j_jcv_2015_10_018 crossref_primary_10_1016_j_vaccine_2013_03_058 crossref_primary_10_1002_jmv_25593 crossref_primary_10_2222_jsv_71_45 crossref_primary_10_1016_j_jim_2009_09_010 crossref_primary_10_1128_JVI_00616_18 crossref_primary_10_1086_589862 crossref_primary_10_1128_CVI_00736_13 crossref_primary_10_2165_10489140_000000000_00000 crossref_primary_10_1345_aph_1R742 crossref_primary_10_1186_s12979_017_0107_2 crossref_primary_10_1016_j_clim_2019_07_003 crossref_primary_10_1016_j_vaccine_2019_07_068 crossref_primary_10_1111_cei_12809 crossref_primary_10_1007_s13365_017_0522_3 crossref_primary_10_1016_j_jdermsci_2012_10_015 crossref_primary_10_1016_j_jim_2015_07_011 crossref_primary_10_1586_erv_09_58 crossref_primary_10_1016_j_vaccine_2020_06_062 crossref_primary_10_1186_s12979_021_00249_6 crossref_primary_10_1111_j_1365_2796_2011_02359_x crossref_primary_10_1093_cid_cir970 crossref_primary_10_1093_ofid_ofw184 crossref_primary_10_1016_j_vaccine_2019_10_038 crossref_primary_10_1080_14760584_2018_1538801 crossref_primary_10_3821_1913_701X_144_3_132 crossref_primary_10_1016_j_coviro_2020_09_007 crossref_primary_10_2217_fvl_12_116 crossref_primary_10_7774_cevr_2013_2_2_92 crossref_primary_10_1111_dme_13038 crossref_primary_10_1128_CMR_00052_13 crossref_primary_10_4161_hv_23412 crossref_primary_10_1007_s40520_019_01374_5 crossref_primary_10_1371_journal_ppat_1005892 crossref_primary_10_1016_j_antiviral_2020_104938 crossref_primary_10_1016_j_rmr_2019_07_008 crossref_primary_10_1177_0961203312470186 crossref_primary_10_3390_vaccines10122155 crossref_primary_10_1684_ecn_2020_0441 crossref_primary_10_1073_pnas_1400476111 crossref_primary_10_2188_jea_JE20140210 crossref_primary_10_1007_s00251_017_1047_x crossref_primary_10_1016_j_ejim_2013_12_004 crossref_primary_10_1016_j_npg_2023_04_006 crossref_primary_10_1586_14760584_2014_924403 crossref_primary_10_1172_JCI123217 crossref_primary_10_1080_21645515_2019_1589282 crossref_primary_10_3390_jcm13237321 crossref_primary_10_1038_s41598_017_01024_8 crossref_primary_10_1093_cid_cis1208 crossref_primary_10_1080_14760584_2017_1395703 crossref_primary_10_1093_ibd_izy150 crossref_primary_10_3390_vaccines11111679 crossref_primary_10_1093_infdis_jit182 crossref_primary_10_1093_infdis_jiv480 crossref_primary_10_1093_infdis_jiv481 crossref_primary_10_7554_eLife_07116 crossref_primary_10_1002_14651858_CD001833_pub3 crossref_primary_10_1016_j_joms_2014_05_004 crossref_primary_10_1007_s40265_013_0088_1 crossref_primary_10_1128_JVI_00002_18 crossref_primary_10_1136_bmj_n188 crossref_primary_10_1371_journal_ppat_1002367 crossref_primary_10_1016_j_vaccine_2011_11_096 crossref_primary_10_1111_1346_8138_14168 crossref_primary_10_1002_jmv_25391 crossref_primary_10_1016_S1386_6532_10_70004_4 crossref_primary_10_4161_hv_7_10_16480 crossref_primary_10_5021_ad_2011_23_1_39 crossref_primary_10_1016_j_vaccine_2015_01_085 crossref_primary_10_1093_infdis_jiw462 crossref_primary_10_1136_bmjopen_2017_017391 crossref_primary_10_1093_infdis_jiu279 crossref_primary_10_1016_j_vacun_2014_03_001 crossref_primary_10_1080_21645515_2017_1317410 crossref_primary_10_1016_S2665_9913_24_00019_5 crossref_primary_10_1080_21645515_2018_1560918 crossref_primary_10_1586_erv_09_12 crossref_primary_10_3389_fimmu_2018_00046 crossref_primary_10_1016_j_vaccine_2019_02_048 crossref_primary_10_1016_S1473_3099_16_00133_X crossref_primary_10_1038_srep07371 crossref_primary_10_1016_j_jdermsci_2022_04_001 crossref_primary_10_1093_infdis_jiy095 crossref_primary_10_3389_fimmu_2016_00530 crossref_primary_10_1126_scitranslmed_aaf1725 crossref_primary_10_1111_ijcp_12508 crossref_primary_10_1016_j_coi_2019_02_005 crossref_primary_10_1038_s41541_022_00545_2 crossref_primary_10_1016_j_virs_2022_06_002 crossref_primary_10_1172_JCI121484 crossref_primary_10_1093_aje_kwy076 crossref_primary_10_1111_jocd_14268 crossref_primary_10_1016_j_rdc_2016_09_010 crossref_primary_10_1016_j_vaccine_2017_08_029 crossref_primary_10_4167_jbv_2021_51_3_103 crossref_primary_10_3390_pathogens8030147 crossref_primary_10_1007_s11553_010_0228_3 crossref_primary_10_1080_07853890_2017_1417632 crossref_primary_10_3389_fimmu_2022_919806 crossref_primary_10_1016_j_celrep_2024_114062 crossref_primary_10_1007_s10389_011_0481_8 crossref_primary_10_1016_j_coviro_2013_04_004 crossref_primary_10_1016_j_vaccine_2024_02_055 crossref_primary_10_1097_INF_0b013e3181998f06 crossref_primary_10_1016_j_vaccine_2010_04_003 crossref_primary_10_1038_s41541_024_00937_6 crossref_primary_10_1093_infdis_jiy420 crossref_primary_10_1128_CVI_00095_12 crossref_primary_10_1016_j_vaccine_2012_01_088 crossref_primary_10_1016_S1576_9887_10_70023_6 crossref_primary_10_1038_jid_2015_63 crossref_primary_10_1128_CVI_00407_08 crossref_primary_10_31482_mmsl_2018_011 crossref_primary_10_1002_jmv_29667 crossref_primary_10_1093_ofid_ofaa172 crossref_primary_10_1128_JVI_02127_19 crossref_primary_10_1111_j_1532_5415_2010_02772_x crossref_primary_10_1136_bmj_k4029 crossref_primary_10_3389_fmed_2022_850762 crossref_primary_10_1128_CVI_00338_08 crossref_primary_10_1177_2054270415577762 crossref_primary_10_1111_j_1469_0691_2012_03944_x crossref_primary_10_1093_infdis_jiv164 crossref_primary_10_1093_infdis_jiu500 crossref_primary_10_1056_NEJMoa2028436 crossref_primary_10_1016_j_coi_2012_06_002 crossref_primary_10_1017_S0950268812002671 crossref_primary_10_1016_j_vaccine_2011_08_046 crossref_primary_10_1080_21645515_2015_1037999 crossref_primary_10_1007_s10616_021_00468_1 crossref_primary_10_1093_infdis_jiz653 crossref_primary_10_1128_mbio_01864_22 crossref_primary_10_4167_jbv_2013_43_4_253 crossref_primary_10_3389_fimmu_2015_00553 crossref_primary_10_1016_j_ijbiomac_2024_134012 crossref_primary_10_1093_infdis_jiy320 crossref_primary_10_4081_monaldi_2022_2414 crossref_primary_10_1371_journal_pone_0258743 crossref_primary_10_1016_j_vaccine_2011_08_052 crossref_primary_10_15844_pedneurbriefs_22_3_10 crossref_primary_10_1080_21645515_2025_2473795 crossref_primary_10_1186_s12879_017_2815_9 crossref_primary_10_1002_art_38745 crossref_primary_10_3390_biom14070739 crossref_primary_10_3346_jkms_2019_34_e1 crossref_primary_10_1038_s41541_024_00840_0 crossref_primary_10_14745_ccdr_v36i00a01 crossref_primary_10_3899_jrheum_130170 crossref_primary_10_1016_j_idc_2017_07_016 crossref_primary_10_1128_CVI_00818_13 crossref_primary_10_2146_ajhp090118 crossref_primary_10_3390_microorganisms12040775 crossref_primary_10_3390_vaccines10010074 crossref_primary_10_1038_s41541_021_00377_6 crossref_primary_10_1016_j_npg_2015_05_004 crossref_primary_10_1093_cid_cis547 crossref_primary_10_1371_journal_pone_0066485 crossref_primary_10_1093_infdis_jix484 crossref_primary_10_5009_gnl18304 crossref_primary_10_1093_infdis_jir138 crossref_primary_10_1371_journal_ppat_1003076 crossref_primary_10_1080_08830185_2021_1925267 crossref_primary_10_3389_fvets_2021_654289 crossref_primary_10_3165_jjpn_cr_2020_0185 crossref_primary_10_1146_annurev_immunol_032414_112315 crossref_primary_10_1016_j_vaccine_2011_09_079 crossref_primary_10_1128_CVI_00131_10 crossref_primary_10_1093_infdis_jix257 crossref_primary_10_1007_s00592_023_02127_7 crossref_primary_10_1016_j_bbi_2011_02_001 crossref_primary_10_1016_j_cger_2017_08_006 crossref_primary_10_1002_jmv_25543 crossref_primary_10_1186_s12865_022_00503_6 crossref_primary_10_1007_s40588_019_00119_2 crossref_primary_10_1128_JVI_00305_19 crossref_primary_10_1089_aid_2010_0340 crossref_primary_10_1016_j_vaccine_2011_03_018 crossref_primary_10_1038_ni_2039 crossref_primary_10_4049_jimmunol_1700290 crossref_primary_10_1016_j_vaccine_2016_10_055 crossref_primary_10_1016_j_jinf_2014_08_016 crossref_primary_10_1080_21645515_2016_1225635 crossref_primary_10_4110_in_2016_16_5_286 crossref_primary_10_1016_j_vaccine_2017_11_019 crossref_primary_10_1586_17469899_2015_1004315 crossref_primary_10_3389_fcimb_2019_00299 crossref_primary_10_1093_infdis_jit342 crossref_primary_10_1007_s40266_018_0603_x crossref_primary_10_1016_j_vaccine_2014_01_019 crossref_primary_10_1128_JVI_00240_21 crossref_primary_10_1007_s11553_010_0240_7 crossref_primary_10_1016_j_immuni_2010_10_006 crossref_primary_10_1016_j_jaci_2020_03_017 crossref_primary_10_1097_QAI_0b013e31819550a4 crossref_primary_10_1111_j_1365_2990_2011_01167_x crossref_primary_10_3899_jrheum_170936 crossref_primary_10_1002_art_40187 crossref_primary_10_1080_14760584_2018_1495565 crossref_primary_10_1016_S1473_3099_16_00174_2 crossref_primary_10_3389_fimmu_2020_00717 crossref_primary_10_2222_jsv_59_249 crossref_primary_10_1093_infdis_jiad259 crossref_primary_10_3390_vaccines11020259 crossref_primary_10_1007_s40259_016_0180_7 crossref_primary_10_1093_infdis_jit344 crossref_primary_10_1016_j_amepre_2017_08_029 crossref_primary_10_1093_infdis_jis497 crossref_primary_10_1093_infdis_jiad132 crossref_primary_10_3390_microorganisms12081506 crossref_primary_10_1517_14712598_2013_830101 crossref_primary_10_1016_j_jaad_2015_12_059 crossref_primary_10_1016_j_mcna_2013_02_002 crossref_primary_10_1093_aje_kws370 crossref_primary_10_1007_s40266_014_0193_1 crossref_primary_10_1042_BST20190511 crossref_primary_10_1016_j_jcv_2012_06_008 crossref_primary_10_1016_j_vaccine_2017_07_099 crossref_primary_10_1016_j_eimc_2015_05_005 crossref_primary_10_1016_j_lpm_2015_10_015 crossref_primary_10_1172_JCI124473 crossref_primary_10_3389_fimmu_2023_1190339 crossref_primary_10_3390_vaccines10040529 crossref_primary_10_7326_M20_6928 crossref_primary_10_1158_1535_7163_MCT_15_0475 crossref_primary_10_2217_ahe_10_5 crossref_primary_10_1093_cid_ciz770 crossref_primary_10_1172_JCI172634 crossref_primary_10_1111_hiv_13548 crossref_primary_10_1111_j_1365_2796_2011_02474_x crossref_primary_10_1111_tid_12874 crossref_primary_10_1016_j_healun_2020_09_013 crossref_primary_10_1007_s10067_019_04563_9 crossref_primary_10_1002_14651858_CD008858_pub3 crossref_primary_10_1002_14651858_CD008858_pub5 crossref_primary_10_1093_infdis_jiy383 crossref_primary_10_1002_14651858_CD008858_pub4 crossref_primary_10_1093_infdis_jiy382 crossref_primary_10_3390_pathogens2020364 crossref_primary_10_1128_JVI_03124_14 crossref_primary_10_1016_j_jiph_2022_05_014 crossref_primary_10_1016_j_vaccine_2015_04_090 crossref_primary_10_1007_s13365_011_0048_z crossref_primary_10_1016_j_coviro_2011_07_007 crossref_primary_10_3390_vaccines12060566 crossref_primary_10_1097_ICO_0000000000000362 crossref_primary_10_4110_in_2019_19_e37 crossref_primary_10_2147_JPR_S409616 crossref_primary_10_1016_j_vaccine_2011_04_019 crossref_primary_10_1093_infdis_jit365 crossref_primary_10_1002_jmv_29821 crossref_primary_10_3390_vaccines12111289 crossref_primary_10_1016_j_cgh_2020_10_027 crossref_primary_10_1128_JVI_00269_18 crossref_primary_10_3947_ic_2018_50_4_311 crossref_primary_10_1080_21645515_2023_2175558 |
| Cites_doi | 10.1016/S0891-5520(05)70319-6 10.1128/CDLI.5.6.804-807.1998 10.1128/IAI.32.1.24-27.1981 10.1093/infdis/153.5.840 10.1086/320169 10.1212/WNL.45.12_Suppl_8.S41 10.1093/infdis/140.6.851 10.1128/IAI.20.3.646-651.1978 10.1086/514272 10.1056/NEJM200003023420906 10.1093/infdis/165.1.119 10.1056/NEJMcp013211 10.1212/WNL.30.6.582 10.1001/archinte.142.2.291 10.1097/00006454-200207000-00002 10.1002/jmv.20754 10.1097/00005792-198209000-00003 10.1001/archinte.155.15.1605 10.1016/0168-8510(96)00822-6 10.1016/0022-1759(94)90242-9 10.1056/NEJMoa051016 10.1056/NEJMoa013441 10.1128/CDLI.8.5.871-879.2001 10.1136/bmj.37991.511829.F7 10.1016/S0264-410X(99)00510-1 10.1093/infdis/166.2.253 10.1086/514264 10.1111/j.1532-5415.1990.tb01497.x 10.1086/379048 10.1111/j.1532-5415.1998.tb02751.x 10.1016/0304-3959(96)03122-3 |
| ContentType | Journal Article |
| Contributor | Annunziato, Paula Boardman, Kathy D Yeh, S S Keitel, W A Oxman, Michael N Hayward, Anthony R Loutit, J Levin, M J Davis, L E Goodman, R P Gelb, Lawrence Gelb, L D Pachucki, C T Guatelli, J Brooks, P A Arbeit, Robert Silber, Jeffrey L Cotton, D J Peduzzi, Peter N Barry, Patricia Neuzil, K M Chan, Ivan S F Davis, Larry Schmader, Kenneth Levin, Myron J Crawford, G E Arbeit, R D Simberkoff, Michael S Keay, S K Schmader, K E Gershon, Anne A Weinberg, Adriana Betts, R F Marques, A R Greenberg, R N Kauffman, C A Irwin, Michael R Brunell, P Griffin, M R Morrison, V A Serrao, R Soto, N E Straus, Stephen E Toney, J F Gnann, J W Simberkoff, M S Lobo, Z Wright, P F Chan, Christina Y Colling, Cindy L Williams, Heather M Beisel, Chris Holodniy, M Johnson, Gary R |
| Contributor_xml | – sequence: 1 givenname: Michael N surname: Oxman fullname: Oxman, Michael N – sequence: 2 givenname: Robert surname: Arbeit fullname: Arbeit, Robert – sequence: 3 givenname: Patricia surname: Barry fullname: Barry, Patricia – sequence: 4 givenname: Chris surname: Beisel fullname: Beisel, Chris – sequence: 5 givenname: Kathy D surname: Boardman fullname: Boardman, Kathy D – sequence: 6 givenname: Cindy L surname: Colling fullname: Colling, Cindy L – sequence: 7 givenname: Larry surname: Davis fullname: Davis, Larry – sequence: 8 givenname: Lawrence surname: Gelb fullname: Gelb, Lawrence – sequence: 9 givenname: Anne A surname: Gershon fullname: Gershon, Anne A – sequence: 10 givenname: Anthony R surname: Hayward fullname: Hayward, Anthony R – sequence: 11 givenname: Michael R surname: Irwin fullname: Irwin, Michael R – sequence: 12 givenname: Gary R surname: Johnson fullname: Johnson, Gary R – sequence: 13 givenname: Myron J surname: Levin fullname: Levin, Myron J – sequence: 14 givenname: Peter N surname: Peduzzi fullname: Peduzzi, Peter N – sequence: 15 givenname: Kenneth surname: Schmader fullname: Schmader, Kenneth – sequence: 16 givenname: Michael S surname: Simberkoff fullname: Simberkoff, Michael S – sequence: 17 givenname: Stephen E surname: Straus fullname: Straus, Stephen E – sequence: 18 givenname: Adriana surname: Weinberg fullname: Weinberg, Adriana – sequence: 19 givenname: Heather M surname: Williams fullname: Williams, Heather M – sequence: 20 givenname: Jeffrey L surname: Silber fullname: Silber, Jeffrey L – sequence: 21 givenname: Paula surname: Annunziato fullname: Annunziato, Paula – sequence: 22 givenname: Christina Y surname: Chan fullname: Chan, Christina Y – sequence: 23 givenname: Ivan S F surname: Chan fullname: Chan, Ivan S F – sequence: 24 givenname: L E surname: Davis fullname: Davis, L E – sequence: 25 givenname: C A surname: Kauffman fullname: Kauffman, C A – sequence: 26 givenname: S K surname: Keay fullname: Keay, S K – sequence: 27 givenname: A R surname: Marques fullname: Marques, A R – sequence: 28 givenname: N E surname: Soto fullname: Soto, N E – sequence: 29 givenname: P surname: Brunell fullname: Brunell, P – sequence: 30 givenname: J W surname: Gnann fullname: Gnann, J W – sequence: 31 givenname: R surname: Serrao fullname: Serrao, R – sequence: 32 givenname: D J surname: Cotton fullname: Cotton, D J – sequence: 33 givenname: R P surname: Goodman fullname: Goodman, R P – sequence: 34 givenname: R D surname: Arbeit fullname: Arbeit, R D – sequence: 35 givenname: C T surname: Pachucki fullname: Pachucki, C T – sequence: 36 givenname: M J surname: Levin fullname: Levin, M J – sequence: 37 givenname: K E surname: Schmader fullname: Schmader, K E – sequence: 38 givenname: W A surname: Keitel fullname: Keitel, W A – sequence: 39 givenname: R N surname: Greenberg fullname: Greenberg, R N – sequence: 40 givenname: V A surname: Morrison fullname: Morrison, V A – sequence: 41 givenname: P F surname: Wright fullname: Wright, P F – sequence: 42 givenname: M R surname: Griffin fullname: Griffin, M R – sequence: 43 givenname: M S surname: Simberkoff fullname: Simberkoff, M S – sequence: 44 givenname: S S surname: Yeh fullname: Yeh, S S – sequence: 45 givenname: Z surname: Lobo fullname: Lobo, Z – sequence: 46 givenname: M surname: Holodniy fullname: Holodniy, M – sequence: 47 givenname: J surname: Loutit fullname: Loutit, J – sequence: 48 givenname: R F surname: Betts fullname: Betts, R F – sequence: 49 givenname: L D surname: Gelb fullname: Gelb, L D – sequence: 50 givenname: G E surname: Crawford fullname: Crawford, G E – sequence: 51 givenname: J surname: Guatelli fullname: Guatelli, J – sequence: 52 givenname: P A surname: Brooks fullname: Brooks, P A – sequence: 53 givenname: K M surname: Neuzil fullname: Neuzil, K M – sequence: 54 givenname: J F surname: Toney fullname: Toney, J F |
| Copyright | Copyright 2008 Infectious Diseases Society of America 2008 by the Infectious Diseases Society of America 2008 2008 INIST-CNRS |
| Copyright_xml | – notice: Copyright 2008 Infectious Diseases Society of America – notice: 2008 by the Infectious Diseases Society of America 2008 – notice: 2008 INIST-CNRS |
| CorporateAuthor | Veterans Affairs Cooperative Studies Program Shingles Prevention Study Investigators |
| CorporateAuthor_xml | – name: Veterans Affairs Cooperative Studies Program Shingles Prevention Study Investigators |
| DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7T5 7U9 H94 7X8 5PM |
| DOI | 10.1086/528696 |
| DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Immunology Abstracts Virology and AIDS Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1537-6613 |
| EndPage | 835 |
| ExternalDocumentID | PMC4014857 18419349 20189905 10_1086_528696 10.1086/528696 30088250 ark_67375_HXZ_RMN9VC7D_G |
| Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIMH NIH HHS grantid: R01 MH055253 – fundername: NCRR NIH HHS grantid: M01-RR00865 – fundername: NIA NIH HHS grantid: P60 AG10415 – fundername: NIAID NIH HHS grantid: U01 AI068632 – fundername: NIAID NIH HHS grantid: UM1 AI068632 – fundername: NIA NIH HHS grantid: P60 AG010415 – fundername: NIAMS NIH HHS grantid: R01 AR049840 – fundername: NINR NIH HHS grantid: R01 NR009228 – fundername: NIMH NIH HHS grantid: R01 MH55253 – fundername: NICHD NIH HHS grantid: N01-HD-3-3345 |
| GroupedDBID | --- -DZ -~X ..I .2P .I3 .XZ .ZR 08P 0R~ 123 1TH 29K 2AX 2WC 36B 4.4 48X 53G 5GY 5RE 5VS 5WD 70D 85S AABZA AACGO AACZT AAHBH AAHTB AAJKP AAJQQ AAMVS AANCE AAOGV AAPNW AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP AAWTL ABBHK ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABOCM ABPEJ ABPLY ABPPZ ABPQP ABPTD ABQLI ABQNK ABTLG ABVGC ABWST ABXSQ ABXVV ABZBJ ACGFO ACGFS ACGOD ACHIC ACPRK ACUFI ACUTO ACYHN ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADQXQ ADRTK ADULT ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEUPB AEWNT AEXZC AFFNX AFFZL AFIYH AFOFC AFXAL AFYAG AGINJ AGKEF AGORE AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AIAGR AIJHB AJBYB AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN AQVQM ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BR6 BSCLL BTRTY BVRKM C45 CDBKE CS3 CZ4 D-I DAKXR DCCCD DIK DILTD DU5 D~K EBS ECGQY EE~ EJD EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HQ3 HTVGU HW0 HZ~ IH2 IOX IPSME J21 JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JST JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B LSO LU7 MHKGH MJL ML0 N4W N9A NGC NOMLY NOYVH NU- NVLIB O0~ O9- OAUYM OAWHX OCZFY ODMLO OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q1. Q5Y QBD RD5 ROX ROZ RUSNO RW1 RXO SA0 SJN TCURE TEORI TJX TR2 W2D W8F WH7 X7H YAYTL YKOAZ YXANX ~91 AAYOK AASNB ADACV ADJQC ADRIX AFXEN DOOOF ESX JSODD M49 AAYXX CITATION .55 .GJ 1KJ 3O- 41~ AAFWJ AAPGJ AAWDT ABDPE ABSMQ ACFRR ACPQN ACUTJ ACVCV ACZBC ADMTO AEKPW AFFQV AFHKK AFQQW AFSHK AGKRT AGMDO AHGBF AI. AJDVS APJGH AQDSO AQKUS AVNTJ BZKNY EIHJH IQODW J5H MBLQV MVM NEJ OBFPC O~Y P0- TMA VH1 X7M Y6R ZE2 ZGI ZXP CGR CUY CVF ECM EIF NPM 7T5 7U9 H94 7X8 5PM |
| ID | FETCH-LOGICAL-c511t-ae7b48206da7a206a41540b843e92ba5a3033bf70d472f148dcae535bee80ec53 |
| ISSN | 0022-1899 |
| IngestDate | Thu Aug 21 18:21:05 EDT 2025 Thu Jul 10 23:48:11 EDT 2025 Thu Jul 10 17:49:15 EDT 2025 Fri May 30 11:01:37 EDT 2025 Mon Jul 21 09:15:55 EDT 2025 Tue Jul 01 03:24:00 EDT 2025 Thu Apr 24 23:12:17 EDT 2025 Wed Sep 11 04:50:44 EDT 2024 Fri Jun 20 02:32:05 EDT 2025 Tue Aug 05 16:50:13 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Human Varicella zoster virus Skin disease Nervous system diseases Herpes zoster Immune response Herpesviridae Alphaherpesvirinae Recipient Vaccine Infection Virus Viral disease Elderly |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c511t-ae7b48206da7a206a41540b843e92ba5a3033bf70d472f148dcae535bee80ec53 |
| Notes | ark:/67375/HXZ-RMN9VC7D-G istex:A60A30DAC349D31FAFC07BF3624B0D57352044C0 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://academic.oup.com/jid/article-pdf/197/6/825/18051927/197-6-825.pdf |
| PMID | 18419349 |
| PQID | 20944558 |
| PQPubID | 23462 |
| PageCount | 11 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4014857 proquest_miscellaneous_69115580 proquest_miscellaneous_20944558 pubmed_primary_18419349 pascalfrancis_primary_20189905 crossref_primary_10_1086_528696 crossref_citationtrail_10_1086_528696 oup_primary_10_1086_528696 jstor_primary_30088250 istex_primary_ark_67375_HXZ_RMN9VC7D_G |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2008-03-15 |
| PublicationDateYYYYMMDD | 2008-03-15 |
| PublicationDate_xml | – month: 03 year: 2008 text: 2008-03-15 day: 15 |
| PublicationDecade | 2000 |
| PublicationPlace | Chicago, IL |
| PublicationPlace_xml | – name: Chicago, IL – name: United States |
| PublicationTitle | The Journal of infectious diseases |
| PublicationTitleAbbrev | The Journal of Infectious Diseases |
| PublicationTitleAlternate | The Journal of Infectious Diseases |
| PublicationYear | 2008 |
| Publisher | The University of Chicago Press University of Chicago Press |
| Publisher_xml | – name: The University of Chicago Press – name: University of Chicago Press |
| References | rf27_392 rf8_373 rf1_366 Oxman MN (rf20_385) 1995; 45 rf31_396 Berger R (rf11_376) 1981; 32 Levin MJ (rf37_402) 1979; 140 rf14_379 rf32_397 Hope-Simpson RE (rf4_369) 1965; 58 Wilson A (rf16_381) 1992; 165 rf7_372 rf21_386 Levin MJ (rf13_378) 1992; 166 Levin MJ (rf19_384) 2001 rf38_403 rf17_382 Schmader KE (rf35_400) 1990; 38 rf28_393 Ljungman P (rf15_380) 1986; 153 rf12_377 rf33_398 rf5_370 rf22_387 rf23_388 rf6_371 rf29_394 rf18_383 Schmader KE (rf36_401) 1998; 46 Zaia JA (rf25_390) 1978; 20 rf2_367 rf9_374 Weinberg A (rf24_389) 1998; 5 rf30_395 rf34_399 rf3_368 rf26_391 Miller AE (rf10_375) 1980; 30 |
| References_xml | – ident: rf18_383 doi: 10.1016/S0891-5520(05)70319-6 – volume: 5 start-page: 804 year: 1998 ident: rf24_389 publication-title: Clin Diagn Lab Immunol doi: 10.1128/CDLI.5.6.804-807.1998 – volume: 32 start-page: 24 year: 1981 ident: rf11_376 publication-title: Infect Immun doi: 10.1128/IAI.32.1.24-27.1981 – volume: 153 start-page: 840 year: 1986 ident: rf15_380 publication-title: J Infect Dis doi: 10.1093/infdis/153.5.840 – ident: rf8_373 doi: 10.1086/320169 – volume: 45 start-page: S41 year: 1995 ident: rf20_385 publication-title: Neurology doi: 10.1212/WNL.45.12_Suppl_8.S41 – volume: 140 start-page: 851 year: 1979 ident: rf37_402 publication-title: J Infect Dis doi: 10.1093/infdis/140.6.851 – volume: 20 start-page: 646 year: 1978 ident: rf25_390 publication-title: Infect Immun doi: 10.1128/IAI.20.3.646-651.1978 – ident: rf27_392 doi: 10.1086/514272 – ident: rf2_367 doi: 10.1056/NEJM200003023420906 – volume: 165 start-page: 119 year: 1992 ident: rf16_381 publication-title: J Infect Dis doi: 10.1093/infdis/165.1.119 – ident: rf1_366 doi: 10.1056/NEJMcp013211 – start-page: 1 year: 2001 ident: rf19_384 publication-title: Arch Virology Suppl – ident: rf26_391 – volume: 30 start-page: 582 year: 1980 ident: rf10_375 publication-title: Neurology doi: 10.1212/WNL.30.6.582 – ident: rf12_377 doi: 10.1001/archinte.142.2.291 – ident: rf38_403 doi: 10.1097/00006454-200207000-00002 – ident: rf29_394 doi: 10.1002/jmv.20754 – ident: rf32_397 – ident: rf5_370 doi: 10.1097/00005792-198209000-00003 – ident: rf6_371 doi: 10.1001/archinte.155.15.1605 – ident: rf30_395 doi: 10.1016/0168-8510(96)00822-6 – ident: rf23_388 doi: 10.1016/0022-1759(94)90242-9 – ident: rf9_374 doi: 10.1056/NEJMoa051016 – ident: rf3_368 – ident: rf17_382 doi: 10.1056/NEJMoa013441 – ident: rf28_393 doi: 10.1128/CDLI.8.5.871-879.2001 – ident: rf34_399 doi: 10.1136/bmj.37991.511829.F7 – volume: 58 start-page: 9 year: 1965 ident: rf4_369 publication-title: Proc R Soc Med – ident: rf22_387 doi: 10.1016/S0264-410X(99)00510-1 – volume: 166 start-page: 253 year: 1992 ident: rf13_378 publication-title: J Infect Dis doi: 10.1093/infdis/166.2.253 – ident: rf33_398 – ident: rf21_386 doi: 10.1086/514264 – volume: 38 start-page: 1188 year: 1990 ident: rf35_400 publication-title: J Am Geriatr Soc doi: 10.1111/j.1532-5415.1990.tb01497.x – ident: rf14_379 doi: 10.1086/379048 – volume: 46 start-page: 973 year: 1998 ident: rf36_401 publication-title: J Am Geriatr Soc doi: 10.1111/j.1532-5415.1998.tb02751.x – ident: rf7_372 doi: 10.1016/0304-3959(96)03122-3 – ident: rf31_396 |
| SSID | ssj0004367 |
| Score | 2.4297237 |
| Snippet | BackgroundA double-blind, placebo-controlled trial that involved 38,546 subjects ⩾60 years old demonstrated efficacy of a high-potency live-attenuated... Background. A double-blind, placebo-controlled trial that involved 38,546 subjects ≥60 years old demonstrated efficacy of a high-potency live-attenuated... A double-blind, placebo-controlled trial that involved 38,546 subjects > or =60 years old demonstrated efficacy of a high-potency live-attenuated Oka/Merck... Background. A double-blind, placebo-controlled trial that involved 38,546 subjects .60 years old demonstrated efficacy of a high-potency live-attenuated... Background A double-blind, placebo-controlled trial that involved 38,546 subjects ⩾60 years old demonstrated efficacy of a high-potency live-attenuated... |
| SourceID | pubmedcentral proquest pubmed pascalfrancis crossref oup jstor istex |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 825 |
| SubjectTerms | Age Factors Age groups Aged Antibodies Antibodies, Viral - blood Applied microbiology Biological and medical sciences Double-Blind Method Female Fundamental and applied biological sciences. Psychology Geometric mean Herpes zoster Herpes Zoster - immunology Herpes Zoster - prevention & control Herpes Zoster - virology Herpes zoster vaccine Herpes Zoster Vaccine - blood Herpes Zoster Vaccine - immunology Herpes Zoster Vaccine - pharmacokinetics Herpes Zoster Vaccine - therapeutic use Herpesvirus 3, Human - immunology Human viral diseases Humans Immunity, Cellular Immunology Infectious diseases Major And Brief Reports Male Medical sciences Microbiology Miscellaneous Older adults Placebos Vaccination Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, Attenuated - immunology Vaccines, Attenuated - pharmacokinetics Vaccines, Attenuated - therapeutic use Varicella zoster encephalitis Varicella-zoster virus Viral diseases Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye Virology Viruses |
| Title | Varicella-Zoster Virus–Specific Immune Responses in Elderly Recipients of a Herpes Zoster Vaccine |
| URI | https://api.istex.fr/ark:/67375/HXZ-RMN9VC7D-G/fulltext.pdf https://www.jstor.org/stable/30088250 https://www.ncbi.nlm.nih.gov/pubmed/18419349 https://www.proquest.com/docview/20944558 https://www.proquest.com/docview/69115580 https://pubmed.ncbi.nlm.nih.gov/PMC4014857 |
| Volume | 197 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKJhASQjAYdMDwA_BSZUobO5cnhHahlLaTUDtVvEQniSMKU1b1gth-PefYuXXrxOUlrZIjx-r32T22v3MOY2-EouSSLnpuIgZLKKWsIG0rK0kcSCSllwHa7xgM3e5Y9CZy0mi8r6mWVsvoIL7aGFfyP6jiPcSVomT_AdmyUbyB3xFfvCLCeP0rjM-AUgIhkNYVxWrMWz-n89XCouhJUgC1phT8QXVRtA5WS69aispyn1-2KKvFbKpyFQygxzifoUXREMTlifv3ilC9ep4Jo-JaLYpDntI77-OfrZEIV4dOp8VW66A6_Ck3q3tViEResUtv1-dixmJPQgfpmajMWoxA2zelj8p51ghxc0LVZ03fxD7fmM1tfbgkO74bbEiXPTwNT8b9fjg6nozusO0OrhOohMXRp89VYKzjekW6eOpOrbiUaXXNG9mmgfWrEKYWEY8PZrDA4ZKaOiebFiLX9bQ1B2X0iD3MoeEfDE0es4bKdthdU2v0cofdG-QqiicMrvOGr_OGG97wkjd8mvGcN7ziDb9IOXDDG140ZHjzlI1PjkeHXSsvtWHF6HEvLVBeJCiVfwIe4AegXyfsyBeOCjoRSEBPx4lSz06E10lxeCcxKOnISCnfVrF0dtlWdpGp54yrVMoY4gRUlAg6dna9diQSSBzZVhBBk70tfvIwzvPQUzmU81DrIXw3NNA02evSbmYyr9yweKcRKx_D_AfpFD0Zdidfwy-DYXB26B2FH5tsV0NaGjo2rSyl3WR7iPGtze-vQV-aoc-MXLIl9rDgQoiTssYtUzju0CIQQkr_dgsXnQw0wB48M9ypOuELXFSJoMm8NVaVBpQQfv1JNv2mE8MLOh6Q3t4f3_qC3a-G7Uu2tZyv1Ct0rpfRvh5AvwG-EtQO |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Varicella-zoster+virus-specific+immune+responses+in+elderly+recipients+of+a+herpes+zoster+vaccine&rft.jtitle=The+Journal+of+infectious+diseases&rft.au=Levin%2C+M+J&rft.au=Oxman%2C+M+N&rft.au=Zhang%2C+J+H&rft.au=Johnson%2C+G+R&rft.date=2008-03-15&rft.issn=0022-1899&rft.volume=197&rft.issue=6&rft.spage=825&rft_id=info:doi/10.1086%2F528696&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1899&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1899&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1899&client=summon |